Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.
Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK.
A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj.
Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS.
In the competitive world of cancer treatment it’s becoming ever more important to stand out from the crowd. LSIPR speaks to TapImmune’s chief executive Glynn Wilson on why he thinks the company does.
The Bay Area of California has one of the greatest concentrations of life sciences companies in the world, but its biotech community is being threatened by the seemingly unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, vice chair, of the new North Bay Life Science Alliance to find out how it plans to strengthen the network in the area.
Earlier this month, the first LSIPR roundtable discussion took place in a London hotel, chaired by managing editor Martin Essex, with six invited experts and deputy editor Ed Conlon taking part. We’ll be publishing a special report on the event but, to whet your appetite, here’s how the discussion began—with a lively debate on the USPTO’s guidelines on patent-eligible subject matter in the wake of the Myriad and Mayo court decisions.
Increasing numbers of patent challengers are finding the USPTO’s post-grant procedures to be attractive alternatives to district court litigation, write Arlene Chow and Peter Noh.
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch.
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies.